We believe in being the change we wish to see in the world.
Artrya Ltd
John Konstantopoulos
With the skills gained providing strategic advice to boards and executives globally on the impact of digital disruption, John Konstantopoulos is instrumental in Artrya’s pursuit to help solve coronary artery disease.
Mark Wainwright
An experienced online business builder and Chartered Accountant, Mark co-founded, led and grew two cutting-edge online businesses and has broad experience across all aspects of establishing and growing start-ups in the exciting, highly competitive and fast-moving tech sector.
Dr Jacob Agris
Dr Agris is a senior healthcare executive, thought leader and accomplished physician with computer engineering doctoral studies in analytics and machine learning.
Dr Julien Flack
With nearly 3 decades of experience, Dr. Flack brings a broad range of software engineering skills and technical leadership to Artrya. He is renowned as a strong communicator with a robust research background and author of several international papers and patents.
Professor Girish Dwivedi, MD
As Artrya’s Chief Scientific Officer, Professor Girish Dwivedi, MD is excited to be working within the MedTech industry to innovate and create solutions using advanced technology, such as AI, to improve health.
Janice Marcon
Janice has extensive experience building and sustaining a high-performance culture within an organization. She is passionate about developing eclectic teams that work cohesively to achieve a company’s objectives.
Riaz Kingston
Riaz has more than 20 years of medical imaging experience, having originally trained as a Radiographer, and brings extensive clinical, business development and sales skills to Artrya.
Dr Abdul Rahman Ihdayhid
As a leader in coronary artery disease diagnosis and treatment, Dr. Ihdayhid uses his practical and academic knowledge to inform Artrya’s research and development, including testing and validating product accuracy and efficacy. He also assists with clinical education and awareness and is a key opinion leader on the benefits of early, non-invasive coronary artery disease diagnosis.